Bell Biosystems Overview
- Year Founded
-
2009
- Status
-
Out of Business
- Employees
-
12
- Latest Deal Type
-
Out of Business
Bell Biosystems General Information
Description
Developer of a cell therapeutic technology designed to create tools to accelerate the progress of innovations in oncology and cell therapy research. The company's technology delivers synthetic and artificial self-replicating contrast agents that enable therapeutic cells to be tracked in-vivo, enabling medical organizations to track, control and destroy transplanted cells.
Contact Information
Website
www.bellbiosystems.comCorporate Office
- 626 Bancroft Way
- Suite A
- Berkeley, CA 94710
- United States
Corporate Office
- 626 Bancroft Way
- Suite A
- Berkeley, CA 94710
- United States
Bell Biosystems Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 9. Out of Business | 01-Jun-2019 | Completed | Out of Business | |||
| 8. Accelerator/Incubator | 01-Jan-2019 | Completed | Generating Revenue | |||
| 7. Later Stage VC | 15-Aug-2018 | Completed | Generating Revenue | |||
| 6. Grant | 07-Sep-2016 | Completed | Generating Revenue | |||
| 5. Early Stage VC (Series A) | 13-Apr-2015 | Completed | Startup | |||
| 4. Accelerator/Incubator | 12-Mar-2014 | Completed | Startup | |||
| 3. Grant | 01-Jul-2012 | Completed | Startup | |||
| 2. Accelerator/Incubator | $20K | Completed | Startup | |||
| 1. Capitalization | $20K | $20K | Completed | Startup |
Bell Biosystems Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series A |
Bell Biosystems Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Bell Biosystems Patents
Bell Biosystems Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2017223718-A1 | Eukaryotic cells with artificial endosymbionts for monitoring duration and persistence of the eukaryotic cell | Inactive | 24-Feb-2016 | ||
| CA-3014914-A1 | Eukaryotic cells with artificial endosymbionts for monitoring duration and persistence of the eukaryotic cell | Inactive | 24-Feb-2016 | ||
| WO-2017147330-A1 | Eukaryotic cells with artificial endosymbionts for monitoring duration and persistence of the eukaryotic cell | Inactive | 24-Feb-2016 | ||
| US-20170239375-A1 | Eukaryotic cells with artificial endosymbionts for monitoring the duration and persistence of the eukaryotic cell | Inactive | 24-Feb-2016 | ||
| WO-2016054298-A1 | Magnetogenetics | Inactive | 01-Oct-2014 | C12N15/1079 |
Bell Biosystems Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Bell Biosystems FAQs
-
When was Bell Biosystems founded?
Bell Biosystems was founded in 2009.
-
Where is Bell Biosystems headquartered?
Bell Biosystems is headquartered in Berkeley, CA.
-
What is the size of Bell Biosystems?
Bell Biosystems has 12 total employees.
-
What industry is Bell Biosystems in?
Bell Biosystems’s primary industry is Discovery Tools (Healthcare).
-
Is Bell Biosystems a private or public company?
Bell Biosystems is a Private company.
-
What is Bell Biosystems’s current revenue?
The current revenue for Bell Biosystems is .
-
How much funding has Bell Biosystems raised over time?
Bell Biosystems has raised $4.28M.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
